Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Adult B Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Adult B Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
Massachusetts General Hospital
Phase 3BBB
DEXAMETHASONE
Mayo Clinic
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB

View all 28 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →